Being short sighted means that vision is blurry when looking at things far away. People with a condition called "pathologic myopia" are short sighted due to problems in the back layer of their eyes, also known as the retina. Some people with pathologic myopia can develop a serious condition called myopic choroidal neovascularization (mCNV). In people with mCNV, new blood vessels grow into the retina. These blood vessels can break, leaking blood or fluid into the retina. This can cause blurry vision or a loss of vision. In this study, researchers will find out more about how well drug aflibercept works and how safe it is in Canadian patients with mCNV. The researchers in this study will review information from the patients' eye doctor visits. The patients in this study will include Canadian men and women who started receiving aflibercept between May 2017 and August 2019. These patients were at least 18 years old and had not received treatment for their mCNV before. The researchers will look at the results of vision tests to find out how well the patients could read from a distance after they received aflibercept for 6 months. They will compare the results of these tests to before the patients received treatment. They will also learn more about how safe it is to have aflibercept injection into the eye.
Study Type
OBSERVATIONAL
Enrollment
28
As prescribed by the treating physician
Many Locations
Multiple Locations, Canada
Change in best corrected visual acuity (BCVA) from baseline to 6 months
BCVA is assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) or Snellen chart with conversion to ETDRS.
Time frame: Baseline to 6 months
Change in BCVA from baseline to 12 months
BCVA is assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) or Snellen chart with conversion to ETDRS.
Time frame: Baseline to 12 months
Central retinal thickness (in μm) measured by Optical coherence tomography (OCT)
Retinal and lesion characteristics were evaluated using spectral domain optical coherence tomography (OCT).
Time frame: At baseline, 6 and 12 months
Number of treatment-emergent adverse events (TEAS's)
TEAEs comprise both ocular and non-ocular TEAEs
Time frame: Baseline to 12 months
Severity of treatment-emergent adverse events
TEAEs comprise both ocular and non-ocular TEAEs
Time frame: Baseline to 12 months
Time from diagnosis to first treatment
Time frame: At 12 months
Number of aflibercept treatments
Time frame: At 12 months
Number of clinic visits
Time frame: At 12 months
Number of visual acuity tests performed
Time frame: At 12 months
Number of imaging assessments performed
Time frame: At 12 months
Type of imaging assessments performed
Imaging assessments as : OCT- Optical coherence tomography; OCTA- Optical coherence tomography angiography; FA- Fluorescein angiography and ICGA- Indocyanine green angiography
Time frame: At 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.